Stocks›Industrials›NEO

NEO NeoGenomics, Inc.

NasdaqResearch view

NeoGenomics, Inc. operates in the Services-Testing Laboratories industry.

$16.65−3.48%
Oct 16 close · 1D EOD · Databento
IndustrialsServices-Testing LaboratoriesMid-capSEC EDGAR FY 2025-12-31

On the WireNo stories on NEO yet. Follow the company and the next one lands in Following.

The numbers · FY2025, filed

SEC EDGAR
Market cap$2.1B
Revenue$727.3M+10.10%
Net income$-108.0M
EPS, diluted$-0.04−300.00%
Gross margin43.2%
Operating margin-15.9%
All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31
SectorIndustrials
Market Cap$2.1B
Enterprise Value$2.3B
Income$-108.0M
Sales$727.3M
Book/sh$6.51
Cash/sh$1.24
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio3.94
Current Ratio4.26
Debt/Eq0.41
EPS (ttm)$-0.04
EPS this Y-300.0%
EPS past 3/5Y—
Sales past 3/5Y12.6%
EPS Y/Y TTM-300.0%
Sales Y/Y TTM10.1%
Shs Outstand128.48M
ROA-7.9%
ROE-12.9%
ROIC-11.1%
Gross Margin43.2%
Oper. Margin-15.9%
Profit Margin-14.8%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$484.3M
FY21
$509.7M
FY22
$591.6M
FY23
$660.6M
FY24
$727.3M
FY25

Operating leverage — margins

GrossOperatingNet
0%40%80%43%-16%-15%FY21FY22FY23FY24FY25
Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it
USDFY2021FY2022FY2023FY2024FY2025

Same industry

In the screener →

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.